News + Resources
“Fast Facts”: Early-Stage Companies Count on M&A to Bring Biopharmaceutical Breakthroughs to Patients
The United States is home to more than 2,300 life sciences companies – including more than 85 percent of the world’s small, early-stage biopharmaceutical companies – each competing to bring new treatments and cures to patients. Within this dynamic and competitive...
Innovations Advanced by M&A: The First Therapy for Pompe Disease
From the complex scientific and regulatory expertise required, to the enormous capital investment needed for state-of-the-art facilities and clinical trials, many companies cannot navigate this path alone. Mergers and acquisitions (M&A) are fundamental to shepherding medicines along the path to market, and to patients in need. Such was the case for a first-of-its-kind treatment for Pompe disease.
House Committee on Small Business Urges FTC, DOJ to Consider Consequences of Recent Merger Guidelines on Early-Stage Companies
Bipartisan policymakers continue to raise concerns about the recently finalized 2023 Merger Guidelines and their impact on early-stage companies. Last week, the House Committee on Small Business wrote to the Federal Trade Commission (FTC) and Antitrust Division of the...
‘Material Differences’ & ‘Less Burden’: FTC, DOJ Signal Forthcoming Changes to Proposed HSR Rules
Speaking to antitrust experts at the ABA’s 2024 Spring Antitrust Meeting, Andrew Forman, deputy assistant attorney general at the Department of Justice’s (DOJ) Antitrust division, suggested that the Federal Trade Commission (FTC) and DOJ’s forthcoming changes to the...
Innovations Advanced by M&A: A Cure for Inherited Blindness
Across the United States’ world-class life sciences ecosystem, mergers and acquisitions (M&A) have become a vital bridge for companies to secure the resources, investment and expertise necessary to bring new treatments and cures to patients. Case in point: the 2019 merger between Roche and Spark Therapeutics that was instrumental in helping to expand the global reach of Luxturna, a first-in-class gene therapy approved as a one-time treatment for biallelic RPE65 mutation-associated retinal dystrophy – a rare, inherited form of vision loss.